title: Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort.
abstract: OBJECTIVE
  To analyze the clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies (ANAs) testing.
  
  
  METHODS
  Sera with a dense fine speckled (DFS) indirect immunofluorescence (IIF) pattern from 100 consecutive patients and 100 patients with other IIF patterns were tested for anti-DFS70 antibodies by a novel chemiluminescence immunoassay (CIA) and for ANA by ANA Screen ELISA (both INOVA).
  
  
  RESULTS
  Among the 100 patients with a DFS IIF pattern, 91% were anti-DFS70 positive by CIA compared to 3% in the comparator group (P < 0.0001). The CIA and IIF titers of anti-DFS antibodies were highly correlated (rho = 0.89). ANA by ELISA was positive in 35% of patients with the DFS IIF pattern as compared to 67% of patients with other patterns (P < 0.0001). Only 12.0% of patients with DFS pattern and 13.4% with DFS pattern and anti-DFS70 antibodies detected by CIA had systemic autoimmune rheumatic disease (SARD). Only 5/91 (5.5%) patients with anti-DFS70 antibodies had SARD and their sera were negative on the ANA Screen ELISA.
  
  
  CONCLUSIONS
  Although anti-DFS70 antibodies cannot exclude the presence of SARD, the likelihood is significantly lower than in patients with other IIF patterns and should be included in test algorithms for ANA testing.
authors.affiliation: Department of Immunology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
authors.forename: Makoto
authors.initials: M
authors.lastname: Miyara
authors.forename: Roger
authors.initials: R
authors.lastname: Albesa
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Charuel
authors.forename: Mohamed
authors.initials: M
authors.lastname: El Amri
authors.forename: Marvin J
authors.initials: MJ
authors.lastname: Fritzler
authors.forename: Pascale
authors.initials: P
authors.lastname: Ghillani-Dalbin
authors.forename: Zahir
authors.initials: Z
authors.lastname: Amoura
authors.forename: Lucile
authors.initials: L
authors.lastname: Musset
authors.forename: Michael
authors.initials: M
authors.lastname: Mahler
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000276:immunology*; D000465:Algorithms; D000906:Antibodies / Q000097:blood; D000974:Antibodies, Antinuclear / Q000097:blood; D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000276:immunology; D015331:Cohort Studies; D003955:Diagnostic Tests, Routine; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000706:statistics & numerical data; D019084:Fluorescent Antibody Technique, Indirect / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D008163:Luminescent Measurements / Q000379:methods / Q000706:statistics & numerical data; D011237:Predictive Value of Tests; D012216:Rheumatic Diseases / Q000175:diagnosis* / Q000276:immunology; D012698:Serologic Tests / Q000379:methods* / Q000706:statistics & numerical data; D062606:Tertiary Care Centers; D014157:Transcription Factors / Q000276:immunology*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000906:Antibodies; D000974:Antibodies, Antinuclear; C504649:PSIP1 protein, human; D014157:Transcription Factors